ABEO Stock Price, Abeona Therapeutics Inc Quote, Chart

Market Summary

USD4.41-0.19

Delayed

-4.13%

ABEO Alerts

JANUS HENDERSON GROUP PLC reported owning 6.1% of ABEO [2024-05-09]

4 major insider buys recently.

ABEO Stock Price

View Fullscreen

ABEO RSI Chart

ABEO Valuation

Market Cap

181.6M

Price/Earnings (Trailing)

-2.37

Price/Sales (Trailing)

51.89

Price/Free Cashflow

-4.46

ABEO Price/Sales (Trailing)

ABEO Profitability

Return on Equity

863.18%

Return on Assets

-102.45%

Free Cashflow Yield

-22.4%

ABEO Fundamentals

ABEO Revenue

Revenue (TTM)

3.5M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

ABEO Earnings

Earnings (TTM)

-76.7M

Earnings Growth (Yr)

-246.74%

Earnings Growth (Qtr)

-90.33%

Breaking Down ABEO Revenue

Last 7 days

5%

Last 30 days

-44.4%

Last 90 days

-37.1%

Trailing 12 Months

47.5%

How does ABEO drawdown profile look like?

ABEO Financial Health

Current Ratio

5.61

ABEO Investor Care

Shares Dilution (1Y)

119.33%

Diluted EPS (TTM)

-2.26

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	1.9M	2.5M	3.0M	3.5M
2022	1.7M	1.6M	1.5M	1.4M
2021	0	0	0	1.8M
2020	0	0	10.0M	12.2M
2018	6.9M	7.5M	9.0M	9.3M
2017	1.0M	843.0K	878.0K	837.0K
2016	1.3M	1.4M	1.5M	1.1M
2015	358.9K	672.8K	986.6K	1.3M
2014	1.0M	806.0K	853.0K	45.0K
2013	3.8M	3.6M	2.9M	2.0M
2012	3.5M	4.1M	3.9M	4.4M
2011	2.0M	1.9M	1.9M	1.8M
2010	0	0	0	2.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Abeona Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 26, 2024	charles faith l.	bought	24,764	3.28	7,550	-
Apr 25, 2024	o'malley brendan m.	bought	27,864	3.24	8,600	svp, general counsel
Apr 25, 2024	vazzano joseph walter	bought	17,609	3.14	5,608	chief financial officer
Apr 25, 2024	seshadri vishwas	bought	32,000	3.2	10,000	chief executive officer
Mar 15, 2024	vazzano joseph walter	sold (taxes)	-5,722	8.14	-703	chief financial officer
Mar 04, 2024	o'malley brendan m.	sold (taxes)	-1,429	7.81	-183	svp, general counsel
Feb 06, 2024	seshadri vishwas	bought	87,800	4.39	20,000	chief executive officer
Jan 17, 2024	alvino mark	sold	-36,199	5.11	-7,084	-
Oct 16, 2023	seshadri vishwas	sold (taxes)	-749	4.14	-181	chief executive officer
Sep 29, 2023	seshadri vishwas	sold (taxes)	-52,229	3.93	-13,290	chief executive officer

Which funds bought or sold ABEO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	57.78	262,861	467,705	-%
May 15, 2024	BARCLAYS PLC	reduced	-66.77	-441,000	409,000	-%
May 15, 2024	Western Standard LLC	added	68.48	5,822,150	9,870,800	4.73%
May 15, 2024	Man Group plc	new	-	535,224	535,224	-%
May 15, 2024	Squarepoint Ops LLC	added	45.2	55,170	105,270	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	701	106,925	117,015	-%
May 15, 2024	Walleye Capital LLC	added	41.54	987,367	1,929,330	-%
May 15, 2024	Ikarian Capital, LLC	added	48.1	3,436,300	6,442,300	0.67%
May 15, 2024	BOOTHBAY FUND MANAGEMENT, LLC	added	68.69	1,157,060	1,959,960	0.04%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-54.95	-89,059	166,816	-%

Are Funds Buying or Selling ABEO?

Are funds buying ABEO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ABEO

No. of Funds

ABEO Alerts

JANUS HENDERSON GROUP PLC reported owning 6.1% of ABEO [2024-05-09]
4 major insider buys recently.

Unveiling Abeona Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 13, 2024	suvretta capital management, llc	9.3%	3,685,503	SC 13G
May 09, 2024	janus henderson group plc	6.1%	2,380,667	SC 13G
Feb 14, 2024	point72 asset management, l.p.	6.4%	1,649,740	SC 13G/A
Feb 14, 2024	armistice capital, llc	4.99%	1,301,114	SC 13G/A
Feb 14, 2024	ecor1 capital, llc	4.2%	1,086,956	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	9.9%	2,499,781	SC 13G/A
Feb 12, 2024	flynn james e	3.39%	869,565	SC 13G/A
Jan 10, 2024	integrated core strategies (us) llc	5.5%	1,363,572	SC 13G/A
Dec 04, 2023	integrated core strategies (us) llc	5.4%	1,334,725	SC 13G
Jul 06, 2023	adage capital partners gp, l.l.c.	15.32%	3,249,994	SC 13G/A

Recent SEC filings of Abeona Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 15, 2024	S-8	Employee Benefits Plan
May 13, 2024	SC 13G	Major Ownership Report
May 09, 2024	SC 13G	Major Ownership Report
May 08, 2024	4	Insider Trading
May 03, 2024	424B5	Prospectus Filed
May 03, 2024	8-K	Current Report
May 03, 2024	8-K	Current Report
Apr 29, 2024	4	Insider Trading

Peers (Alternatives to Abeona Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Abeona Therapeutics Inc News

Latest updates

Abeona Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4	2020Q3	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4
Revenue	-	-	-	-	3,500	1,784	68.00	-	1,000	346	1,673	3,000	7,000	482	1,709	819	6,275	215	219	217	186	256
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	18,492	18,625	12,833	11,214	8,965	5,581	8,657	5,470	6,088
Operating Expenses	8.5%	14,330	13,209	11,334	14,054	12,038	13,004	9,380	9,008	20,937	49,652	17,480	13,248	-	18,625	-	-	-	-	-	-	-
S&GA Expenses	-100.0%	-	5,830	4,156	5,021	3,997	5,682	3,890	3,460	4,224	4,375	7,397	4,432	7,631	4,970	4,627	2,878	-	-	-	-	-
R&D Expenses	-2.3%	7,207	7,379	7,148	8,523	8,041	6,272	5,490	6,658	10,545	12,812	9,243	7,969	9,470	13,150	7,916	-	-	-	-	-	-
Interest Expenses	456.9%	607	109	105	103	101	178	157	200	201	53.00	1,388	1,327	2.00	3.00	3.00	3.00	1.00	-	-	-	-
Net Income	-90.3%	-31,578	-16,591	-11,836	-16,654	-9,107	-7,121	-6,434	-4,097	-22,044	-46,683	-15,828	-7,237	-17,479	-16,419	-12,243	-	-	-	-	-	-
Net Income Margin	-41.5%	-21.90*	-15.48*	-15.01*	-16.00*	-13.83*	-28.07*	-52.84*	-50.36*	-54.41*	-48.31*	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-64.6%	-15,263	-9,272	-5,818	-10,332	-11,918	-14,017	-6,793	-9,013	-13,790	-33,505	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	16.9%	75.00	64.00	66.00	54.00	53.00	64.00	39.00	45.00	55.00	80.00	119	131	141	151	159	164	175	223	143	159	166
Current Assets	19.7%	67.00	56.00	57.00	44.00	43.00	53.00	25.00	30.00	39.00	56.00	68.00	79.00	89.00	98.00	105	109	119	132	50.00	65.00	72.00
Cash Equivalents	23.7%	18.00	14.00	5.00	6.00	5.00	14.00	6.00	6.00	20.00	33.00	44.00	27.00	14.00	13.00	8.00	15.00	40.00	129	48.00	43.00	26.00
Net PPE	6.6%	4.00	4.00	4.00	4.00	5.00	6.00	7.00	7.00	8.00	12.00	10.00	10.00	11.00	11.00	12.00	13.00	13.00	13.00	14.00	14.00	10.00
Goodwill	-	-	-	-	-	-	-	-	-	-	-	32.00	32.00	32.00	32.00	32.00	32.00	32.00	32.00	32.00	32.00	32.00
Liabilities	70.2%	84.00	49.00	44.00	44.00	35.00	37.00	23.00	25.00	24.00	37.00	39.00	47.00	47.00	49.00	44.00	43.00	43.00	45.00	47.00	52.00	48.00
Current Liabilities	-11.4%	12.00	13.00	8.00	9.00	7.00	8.00	13.00	14.00	12.00	17.00	26.00	42.00	41.00	42.00	39.00	38.00	37.00	39.00	20.00	26.00	21.00
Shareholder's Equity	-159.9%	-8.88	15.00	22.00	9.00	19.00	27.00	12.00	14.00	21.00	42.00	80.00	84.00	94.00	103	115	121	132	178	96.00	107	118
Retained Earnings	-4.2%	-781	-749	-732	-721	-704	-695	688	682	-676	-655	-608	-601	-586	-570	-554	-547	-534	-486	-470	-452	-428
Additional Paid-In Capital	1.0%	772	764	755	730	723	722	701	694	697	697	688	685	680	672	669	668	666	664	566	559	546
Shares Outstanding	3.9%	28.00	27.00	25.00	21.00	18.00	18.00	6.00	6.00	6.00	6.00	4.00	4.00	4.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	78.00	-	-	-	29.00	-	-	-	137	-	-	-	204	-	-	-	131	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-57.4%	-14,538	-9,235	-5,774	-10,300	-11,700	-13,992	-6,791	-9,013	-13,687	-30,257	-10,334	-11,489	-13,585	-1,610	-10,702	-9,475	-13,232	-14,246	-18,254	-15,242	-15,078
Share Based Compensation	2.1%	1,546	1,514	1,557	927	770	833	632	724	862	2,001	2,537	2,428	1,950	3,030	161	147	1,256	2,595	98.00	1,678	2,103
Cashflow From Investing	-167.8%	-7,817	11,529	-18,743	5,211	2,211	-25,290	1,649	-1,398	1,075	7,999	26,763	21,924	9,376	5,782	4,584	-18,209	-75,871	-946	19,228	18,920	22,774
Cashflow From Financing	240.7%	25,440	7,467	22,976	6,618	-4.00	42,766	4,189	-	-	16,331	173	2,479	5,878	3.00	-	-	-	96,527	4,340	13,007	28.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ABEO Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
License and other revenues
Expenses:
Research and development	7,207	8,041
General and administrative	7,123	3,997
Total expenses	14,330	12,038
Loss from operations	(14,330)	(12,038)
Interest income	843	364
Interest expense	(952)	(101)
Change in fair value of warrant and derivative liabilities	(17,301)	2,265
Other income	162	403
Net loss	$ (31,578)	$ (9,107)
Loss per common share - basic	$ (1.16)	$ (0.54)
Loss per common share - diluted	$ (1.16)	$ (0.54)
Weighted average number of common shares outstanding - basic	27,315,537	16,904,024
Weighted average number of common shares outstanding - diluted	27,315,537	16,904,024
Other comprehensive income (loss):
Change in unrealized (losses) gains related to available-for-sale debt securities	$ (118)	$ 64
Comprehensive loss	$ (31,696)	$ (9,043)

ABEO Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 17,558	$ 14,473
Short-term investments	44,786	37,753
Restricted cash	338	338
Other receivables	2,232	2,444
Prepaid expenses and other current assets	1,811	729
Total current assets	66,725	55,737
Property and equipment, net	3,767	3,533
Operating lease right-of-use assets	4,222	4,455
Other assets	114	277
Total assets	74,828	64,002
Current liabilities:
Accounts payable	3,362	1,858
Accrued expenses	2,791	5,985
Current portion of operating lease liability	1,044	998
Current portion of payable to licensor	4,691	4,580
Other current liabilities	1	1
Total current liabilities	11,889	13,422
Long-term operating lease liabilities	4,046	4,402
Long-term debt	18,079
Derivative liabilities	1,005
Warrant liabilities	48,690	31,352
Total liabilities	83,709	49,176
Commitments and contingencies
Stockholders’ (deficit) equity:
Preferred stock - $0.01 par value; authorized 2,000,000 shares; No shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively
Common stock - $0.01 par value; authorized 200,000,000 shares; 27,550,593 and 26,523,878 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	276	265
Additional paid-in capital	772,129	764,151
Accumulated deficit	(781,102)	(749,524)
Accumulated other comprehensive loss	(184)	(66)
Total stockholders’ (deficit) equity	(8,881)	14,826
Total liabilities and stockholders’ equity	$ 74,828	$ 64,002

About Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.

CEO	Dr. Vishwas Seshadri M.B.A., Ph.D.
WEBSITE	abeonatherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	57

Abeona Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Abeona Therapeutics Inc? What does ABEO stand for in stocks?

ABEO is the stock ticker symbol of Abeona Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Abeona Therapeutics Inc (ABEO)?

As of Fri May 17 2024, market cap of Abeona Therapeutics Inc is 181.63 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABEO stock?

You can check ABEO's fair value in chart for subscribers.

What is the fair value of ABEO stock?

You can check ABEO's fair value in chart for subscribers. The fair value of Abeona Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Abeona Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABEO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Abeona Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ABEO is over valued or under valued. Whether Abeona Therapeutics Inc is cheap or expensive depends on the assumptions which impact Abeona Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABEO.

What is Abeona Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ABEO's PE ratio (Price to Earnings) is -2.37 and Price to Sales (PS) ratio is 51.89. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABEO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Abeona Therapeutics Inc's stock?

In the past 10 years, Abeona Therapeutics Inc has provided -0.15 (multiply by 100 for percentage) rate of return.